[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy. This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. Eligible participants were of either gender aged between 3 weeks and 7 months old with onset of spinal muscular atrophy symptoms between 3 weeks and 6 months, who had SMN1 homozygous gene deletion or mutation. Safety assessments included adverse events, physical and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laboratory tests, and electrocardiographs. Clinical efficacy assessments included event free survival, and change from baseline of two assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2 (HINE-2) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test, and compound motor action potentials. Autopsy tissue was analysed for target engagement, drug concentrations, and pharmacological activity. HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test. Age at death or permanent ventilation was compared with natural history using the log-rank test. The study is registered at ClinicalTrials.gov, number NCT01839656. 20 participants were enrolled between May 3, 2013, and July 9, 2014, and assessed through to an interim analysis done on Jan 26, 2016. All participants experienced adverse events, with 77 serious adverse events reported in 16 participants, all considered by study investigators not related or unlikely related to the study drug. In the 12 mg dose group, incremental achievements of motor milestones (p<0\u00b70001), improvements in CHOP-INTEND motor function scores (p=0\u00b70013), and increased compound muscle action potential amplitude of the ulnar nerve (p=0\u00b70103) and peroneal nerve (p<0\u00b70001), compared with baseline, were observed. Median age at death or permanent ventilation was not reached and the Kaplan-Meier survival curve diverged from a published natural history case series (p=0\u00b70014). Analysis of autopsy tissue from patients exposed to nusinersen showed drug uptake into motor neurons throughout the spinal cord and neurons and other cell types in the brainstem and other brain regions, exposure at therapeutic concentrations, and increased SMN2 mRNA exon 7 inclusion and SMN protein concentrations in the spinal cord. Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy. Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy. Ionis Pharmaceuticals, Inc and Biogen.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "0ddc50b6e2eb4c54b88303df7172ac37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[120, 122], [99, 101], [15, 17], [546, 548], [51, 53]], "char_spans": [[702, 724], [581, 603], [100, 122], [3221, 3243], [310, 332]]}]}], "context_tokens": [["Nusinersen", 0], ["is", 11], ["a", 14], ["2'-O", 16], ["-", 20], ["methoxyethyl", 21], ["phosphorothioate", 34], ["-", 50], ["modified", 51], ["antisense", 60], ["drug", 70], ["being", 75], ["developed", 81], ["to", 91], ["treat", 94], ["spinal", 100], ["muscular", 107], ["atrophy", 116], [".", 123], ["Nusinersen", 125], ["is", 136], ["specifically", 139], ["designed", 152], ["to", 161], ["alter", 164], ["splicing", 170], ["of", 179], ["SMN2", 182], ["pre", 187], ["-", 190], ["mRNA", 191], ["and", 196], ["thus", 200], ["increase", 205], ["the", 214], ["amount", 218], ["of", 225], ["functional", 228], ["survival", 239], ["motor", 248], ["neuron", 254], ["(", 261], ["SMN", 262], [")", 265], ["protein", 267], ["that", 275], ["is", 280], ["deficient", 283], ["in", 293], ["patients", 296], ["with", 305], ["spinal", 310], ["muscular", 317], ["atrophy", 326], [".", 333], ["This", 335], ["open", 340], ["-", 344], ["label", 345], [",", 350], ["phase", 352], ["2", 358], [",", 359], ["escalating", 361], ["dose", 372], ["clinical", 377], ["study", 386], ["assessed", 392], ["the", 401], ["safety", 405], ["and", 412], ["tolerability", 416], [",", 428], ["pharmacokinetics", 430], [",", 446], ["and", 448], ["clinical", 452], ["efficacy", 461], ["of", 470], ["multiple", 473], ["intrathecal", 482], ["doses", 494], ["of", 500], ["nusinersen", 503], ["(", 514], ["6", 515], ["mg", 517], ["and", 520], ["12", 524], ["mg", 527], ["dose", 530], ["equivalents", 535], [")", 546], ["in", 548], ["patients", 551], ["with", 560], ["infantile", 565], ["-", 574], ["onset", 575], ["spinal", 581], ["muscular", 588], ["atrophy", 597], [".", 604], ["Eligible", 606], ["participants", 615], ["were", 628], ["of", 633], ["either", 636], ["gender", 643], ["aged", 650], ["between", 655], ["3", 663], ["weeks", 665], ["and", 671], ["7", 675], ["months", 677], ["old", 684], ["with", 688], ["onset", 693], ["of", 699], ["spinal", 702], ["muscular", 709], ["atrophy", 718], ["symptoms", 726], ["between", 735], ["3", 743], ["weeks", 745], ["and", 751], ["6", 755], ["months", 757], [",", 763], ["who", 765], ["had", 769], ["SMN1", 773], ["homozygous", 778], ["gene", 789], ["deletion", 794], ["or", 803], ["mutation", 806], [".", 814], ["Safety", 816], ["assessments", 823], ["included", 835], ["adverse", 844], ["events", 852], [",", 858], ["physical", 860], ["and", 869], ["neurological", 873], ["examinations", 886], [",", 898], ["vital", 900], ["signs", 906], [",", 911], ["clinical", 913], ["laboratory", 922], ["tests", 933], [",", 938], ["cerebrospinal", 940], ["fluid", 954], ["laboratory", 960], ["tests", 971], [",", 976], ["and", 978], ["electrocardiographs", 982], [".", 1001], ["Clinical", 1003], ["efficacy", 1012], ["assessments", 1021], ["included", 1033], ["event", 1042], ["free", 1048], ["survival", 1053], [",", 1061], ["and", 1063], ["change", 1067], ["from", 1074], ["baseline", 1079], ["of", 1088], ["two", 1091], ["assessments", 1095], ["of", 1107], ["motor", 1110], ["function", 1116], [":", 1124], ["the", 1126], ["motor", 1130], ["milestones", 1136], ["portion", 1147], ["of", 1155], ["the", 1158], ["Hammersmith", 1162], ["Infant", 1174], ["Neurological", 1181], ["Exam", 1194], ["-", 1198], ["Part", 1199], ["2", 1204], ["(", 1206], ["HINE-2", 1207], [")", 1213], ["and", 1215], ["the", 1219], ["Children", 1223], ["'s", 1231], ["Hospital", 1234], ["of", 1243], ["Philadelphia", 1246], ["Infant", 1259], ["Test", 1266], ["of", 1271], ["Neuromuscular", 1274], ["Disorders", 1288], ["(", 1298], ["CHOP", 1299], ["-", 1303], ["INTEND", 1304], [")", 1310], ["motor", 1312], ["function", 1318], ["test", 1327], [",", 1331], ["and", 1333], ["compound", 1337], ["motor", 1346], ["action", 1352], ["potentials", 1359], [".", 1369], ["Autopsy", 1371], ["tissue", 1379], ["was", 1386], ["analysed", 1390], ["for", 1399], ["target", 1403], ["engagement", 1410], [",", 1420], ["drug", 1422], ["concentrations", 1427], [",", 1441], ["and", 1443], ["pharmacological", 1447], ["activity", 1463], [".", 1471], ["HINE-2", 1473], [",", 1479], ["CHOP", 1481], ["-", 1485], ["INTEND", 1486], [",", 1492], ["and", 1494], ["compound", 1498], ["motor", 1507], ["action", 1513], ["potential", 1520], ["were", 1530], ["compared", 1535], ["between", 1544], ["baseline", 1552], ["and", 1561], ["last", 1565], ["visit", 1570], ["using", 1576], ["the", 1582], ["Wilcoxon", 1586], ["signed", 1595], ["-", 1601], ["rank", 1602], ["test", 1607], [".", 1611], ["Age", 1613], ["at", 1617], ["death", 1620], ["or", 1626], ["permanent", 1629], ["ventilation", 1639], ["was", 1651], ["compared", 1655], ["with", 1664], ["natural", 1669], ["history", 1677], ["using", 1685], ["the", 1691], ["log", 1695], ["-", 1698], ["rank", 1699], ["test", 1704], [".", 1708], ["The", 1710], ["study", 1714], ["is", 1720], ["registered", 1723], ["at", 1734], ["ClinicalTrials.gov", 1737], [",", 1755], ["number", 1757], ["NCT01839656", 1764], [".", 1775], ["20", 1777], ["participants", 1780], ["were", 1793], ["enrolled", 1798], ["between", 1807], ["May", 1815], ["3", 1819], [",", 1820], ["2013", 1822], [",", 1826], ["and", 1828], ["July", 1832], ["9", 1837], [",", 1838], ["2014", 1840], [",", 1844], ["and", 1846], ["assessed", 1850], ["through", 1859], ["to", 1867], ["an", 1870], ["interim", 1873], ["analysis", 1881], ["done", 1890], ["on", 1895], ["Jan", 1898], ["26", 1902], [",", 1904], ["2016", 1906], [".", 1910], ["All", 1912], ["participants", 1916], ["experienced", 1929], ["adverse", 1941], ["events", 1949], [",", 1955], ["with", 1957], ["77", 1962], ["serious", 1965], ["adverse", 1973], ["events", 1981], ["reported", 1988], ["in", 1997], ["16", 2000], ["participants", 2003], [",", 2015], ["all", 2017], ["considered", 2021], ["by", 2032], ["study", 2035], ["investigators", 2041], ["not", 2055], ["related", 2059], ["or", 2067], ["unlikely", 2070], ["related", 2079], ["to", 2087], ["the", 2090], ["study", 2094], ["drug", 2100], [".", 2104], ["In", 2106], ["the", 2109], ["12", 2113], ["mg", 2116], ["dose", 2119], ["group", 2124], [",", 2129], ["incremental", 2131], ["achievements", 2143], ["of", 2156], ["motor", 2159], ["milestones", 2165], ["(", 2176], ["p<0\u00b70001", 2177], [")", 2185], [",", 2186], ["improvements", 2188], ["in", 2201], ["CHOP", 2204], ["-", 2208], ["INTEND", 2209], ["motor", 2216], ["function", 2222], ["scores", 2231], ["(", 2238], ["p=0\u00b70013", 2239], [")", 2247], [",", 2248], ["and", 2250], ["increased", 2254], ["compound", 2264], ["muscle", 2273], ["action", 2280], ["potential", 2287], ["amplitude", 2297], ["of", 2307], ["the", 2310], ["ulnar", 2314], ["nerve", 2320], ["(", 2326], ["p=0\u00b70103", 2327], [")", 2335], ["and", 2337], ["peroneal", 2341], ["nerve", 2350], ["(", 2356], ["p<0\u00b70001", 2357], [")", 2365], [",", 2366], ["compared", 2368], ["with", 2377], ["baseline", 2382], [",", 2390], ["were", 2392], ["observed", 2397], [".", 2405], ["Median", 2407], ["age", 2414], ["at", 2418], ["death", 2421], ["or", 2427], ["permanent", 2430], ["ventilation", 2440], ["was", 2452], ["not", 2456], ["reached", 2460], ["and", 2468], ["the", 2472], ["Kaplan", 2476], ["-", 2482], ["Meier", 2483], ["survival", 2489], ["curve", 2498], ["diverged", 2504], ["from", 2513], ["a", 2518], ["published", 2520], ["natural", 2530], ["history", 2538], ["case", 2546], ["series", 2551], ["(", 2558], ["p=0\u00b70014", 2559], [")", 2567], [".", 2568], ["Analysis", 2570], ["of", 2579], ["autopsy", 2582], ["tissue", 2590], ["from", 2597], ["patients", 2602], ["exposed", 2611], ["to", 2619], ["nusinersen", 2622], ["showed", 2633], ["drug", 2640], ["uptake", 2645], ["into", 2652], ["motor", 2657], ["neurons", 2663], ["throughout", 2671], ["the", 2682], ["spinal", 2686], ["cord", 2693], ["and", 2698], ["neurons", 2702], ["and", 2710], ["other", 2714], ["cell", 2720], ["types", 2725], ["in", 2731], ["the", 2734], ["brainstem", 2738], ["and", 2748], ["other", 2752], ["brain", 2758], ["regions", 2764], [",", 2771], ["exposure", 2773], ["at", 2782], ["therapeutic", 2785], ["concentrations", 2797], [",", 2811], ["and", 2813], ["increased", 2817], ["SMN2", 2827], ["mRNA", 2832], ["exon", 2837], ["7", 2842], ["inclusion", 2844], ["and", 2854], ["SMN", 2858], ["protein", 2862], ["concentrations", 2870], ["in", 2885], ["the", 2888], ["spinal", 2892], ["cord", 2899], [".", 2903], ["Administration", 2905], ["of", 2920], ["multiple", 2923], ["intrathecal", 2932], ["doses", 2944], ["of", 2950], ["nusinersen", 2953], ["showed", 2964], ["acceptable", 2971], ["safety", 2982], ["and", 2989], ["tolerability", 2993], [",", 3005], ["pharmacology", 3007], ["consistent", 3020], ["with", 3031], ["its", 3036], ["intended", 3040], ["mechanism", 3049], ["of", 3059], ["action", 3062], [",", 3068], ["and", 3070], ["encouraging", 3074], ["clinical", 3086], ["efficacy", 3095], [".", 3103], ["Results", 3105], ["informed", 3113], ["the", 3122], ["design", 3126], ["of", 3133], ["an", 3136], ["ongoing", 3139], [",", 3146], ["sham", 3148], ["-", 3152], ["controlled", 3153], [",", 3163], ["phase", 3165], ["3", 3171], ["clinical", 3173], ["study", 3182], ["of", 3188], ["nusinersen", 3191], ["in", 3202], ["infantile", 3205], ["-", 3214], ["onset", 3215], ["spinal", 3221], ["muscular", 3228], ["atrophy", 3237], [".", 3244], ["Ionis", 3246], ["Pharmaceuticals", 3252], [",", 3267], ["Inc", 3269], ["and", 3273], ["Biogen", 3277], [".", 3283]]}
{"context": "Ca2+ is a ubiquitous intracellular messenger responsible for controlling numerous cellular processes including fertilization, mitosis, neuronal transmission, contraction and relaxation of muscles, gene transcription, and cell death. At rest, the cytoplasmic Ca2+ concentration [Ca2+]i is approximately 100 nM, but this level rises to 500-1,000 nM upon activation. In osteoblasts, the elevation of [Ca2+]i is a result of an increase in the release of Ca2+ from endoplasmic reticulum and/or extracellular Ca2+ influx through voltage gated Ca2+ channels. Many of the cellular effects of Ca2+ are mediated by the Ca2+ binding protein, calmodulin (CaM). Upon binding up to four calcium ions, CaM undergoes a conformational change, which enables it to bind to specific proteins eliciting a specific response. Calmodulin kinase II (CaMKII) is a major target of the Ca(2+)/CaM second messenger system. Once bound to Ca(2+)/CaM, the multimeric CaMKII is released from its autoinhibitory status and maximally activated, which then leads to an intraholoenzyme autophosphorylation reaction. Calcineurin (Cn) is another major target protein that is activated by Ca(2+)/CaM. Cn is a serine-threonine phosphatase that consists of a heterodimeric protein complex composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). Upon activation, Cn directly binds to, and dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors within the cytoplasm allowing them to translocate to the nucleus and participate in the regulation of gene expression. This review will examine the potential mechanisms by which calcium, CaM, CaMKII, and Cn/NFAT control osteoblast proliferation and differentiation.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "4739d60b47ce43b3a2834c15aa922cab", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[189, 189]], "char_spans": [[1079, 1089]]}]}], "context_tokens": [["Ca2", 0], ["+", 3], ["is", 5], ["a", 8], ["ubiquitous", 10], ["intracellular", 21], ["messenger", 35], ["responsible", 45], ["for", 57], ["controlling", 61], ["numerous", 73], ["cellular", 82], ["processes", 91], ["including", 101], ["fertilization", 111], [",", 124], ["mitosis", 126], [",", 133], ["neuronal", 135], ["transmission", 144], [",", 156], ["contraction", 158], ["and", 170], ["relaxation", 174], ["of", 185], ["muscles", 188], [",", 195], ["gene", 197], ["transcription", 202], [",", 215], ["and", 217], ["cell", 221], ["death", 226], [".", 231], ["At", 233], ["rest", 236], [",", 240], ["the", 242], ["cytoplasmic", 246], ["Ca2", 258], ["+", 261], ["concentration", 263], ["[", 277], ["Ca2+]i", 278], ["is", 285], ["approximately", 288], ["100", 302], ["nM", 306], [",", 308], ["but", 310], ["this", 314], ["level", 319], ["rises", 325], ["to", 331], ["500", 334], ["-", 337], ["1,000", 338], ["nM", 344], ["upon", 347], ["activation", 352], [".", 362], ["In", 364], ["osteoblasts", 367], [",", 378], ["the", 380], ["elevation", 384], ["of", 394], ["[", 397], ["Ca2+]i", 398], ["is", 405], ["a", 408], ["result", 410], ["of", 417], ["an", 420], ["increase", 423], ["in", 432], ["the", 435], ["release", 439], ["of", 447], ["Ca2", 450], ["+", 453], ["from", 455], ["endoplasmic", 460], ["reticulum", 472], ["and/or", 482], ["extracellular", 489], ["Ca2", 503], ["+", 506], ["influx", 508], ["through", 515], ["voltage", 523], ["gated", 531], ["Ca2", 537], ["+", 540], ["channels", 542], [".", 550], ["Many", 552], ["of", 557], ["the", 560], ["cellular", 564], ["effects", 573], ["of", 581], ["Ca2", 584], ["+", 587], ["are", 589], ["mediated", 593], ["by", 602], ["the", 605], ["Ca2", 609], ["+", 612], ["binding", 614], ["protein", 622], [",", 629], ["calmodulin", 631], ["(", 642], ["CaM", 643], [")", 646], [".", 647], ["Upon", 649], ["binding", 654], ["up", 662], ["to", 665], ["four", 668], ["calcium", 673], ["ions", 681], [",", 685], ["CaM", 687], ["undergoes", 691], ["a", 701], ["conformational", 703], ["change", 718], [",", 724], ["which", 726], ["enables", 732], ["it", 740], ["to", 743], ["bind", 746], ["to", 751], ["specific", 754], ["proteins", 763], ["eliciting", 772], ["a", 782], ["specific", 784], ["response", 793], [".", 801], ["Calmodulin", 803], ["kinase", 814], ["II", 821], ["(", 824], ["CaMKII", 825], [")", 831], ["is", 833], ["a", 836], ["major", 838], ["target", 844], ["of", 851], ["the", 854], ["Ca(2+)/CaM", 858], ["second", 869], ["messenger", 876], ["system", 886], [".", 892], ["Once", 894], ["bound", 899], ["to", 905], ["Ca(2+)/CaM", 908], [",", 918], ["the", 920], ["multimeric", 924], ["CaMKII", 935], ["is", 942], ["released", 945], ["from", 954], ["its", 959], ["autoinhibitory", 963], ["status", 978], ["and", 985], ["maximally", 989], ["activated", 999], [",", 1008], ["which", 1010], ["then", 1016], ["leads", 1021], ["to", 1027], ["an", 1030], ["intraholoenzyme", 1033], ["autophosphorylation", 1049], ["reaction", 1069], [".", 1077], ["Calcineurin", 1079], ["(", 1091], ["Cn", 1092], [")", 1094], ["is", 1096], ["another", 1099], ["major", 1107], ["target", 1113], ["protein", 1120], ["that", 1128], ["is", 1133], ["activated", 1136], ["by", 1146], ["Ca(2+)/CaM.", 1149], ["Cn", 1161], ["is", 1164], ["a", 1167], ["serine", 1169], ["-", 1175], ["threonine", 1176], ["phosphatase", 1186], ["that", 1198], ["consists", 1203], ["of", 1212], ["a", 1215], ["heterodimeric", 1217], ["protein", 1231], ["complex", 1239], ["composed", 1247], ["of", 1256], ["a", 1259], ["catalytic", 1261], ["subunit", 1271], ["(", 1279], ["CnA", 1280], [")", 1283], ["and", 1285], ["a", 1289], ["regulatory", 1291], ["subunit", 1302], ["(", 1310], ["CnB", 1311], [")", 1314], [".", 1315], ["Upon", 1317], ["activation", 1322], [",", 1332], ["Cn", 1334], ["directly", 1337], ["binds", 1346], ["to", 1352], [",", 1354], ["and", 1356], ["dephosphorylates", 1360], ["nuclear", 1377], ["factor", 1385], ["of", 1392], ["activated", 1395], ["T", 1405], ["cells", 1407], ["(", 1413], ["NFAT", 1414], [")", 1418], ["transcription", 1420], ["factors", 1434], ["within", 1442], ["the", 1449], ["cytoplasm", 1453], ["allowing", 1463], ["them", 1472], ["to", 1477], ["translocate", 1480], ["to", 1492], ["the", 1495], ["nucleus", 1499], ["and", 1507], ["participate", 1511], ["in", 1523], ["the", 1526], ["regulation", 1530], ["of", 1541], ["gene", 1544], ["expression", 1549], [".", 1559], ["This", 1561], ["review", 1566], ["will", 1573], ["examine", 1578], ["the", 1586], ["potential", 1590], ["mechanisms", 1600], ["by", 1611], ["which", 1614], ["calcium", 1620], [",", 1627], ["CaM", 1629], [",", 1632], ["CaMKII", 1634], [",", 1640], ["and", 1642], ["Cn", 1646], ["/", 1648], ["NFAT", 1649], ["control", 1654], ["osteoblast", 1662], ["proliferation", 1673], ["and", 1687], ["differentiation", 1691], [".", 1706]]}
{"context": "Viroids are plant subviral pathogens whose genomes are constituted by a single-stranded and covalently closed small RNA molecule that does not encode for any protein. Despite this genomic simplicity, they are able of inducing devastating symptoms in susceptible plants. Most of the 29 described viroid species fold into a rodlike or quasi-rodlike structure, whereas a few of them fold as branched structures. The shape of these RNA structures is perhaps one of the most characteristic properties of viroids and sometimes is considered their only phenotype. Here we use RNA thermodynamic secondary structure prediction algorithms to compare the mutational robustness of all viroid species. After characterizing the statistical properties of the distribution of mutational effects on structure stability and the wideness of neutral neighborhood for each viroid species, we show an evolutionary trend toward increased structural robustness during viroid radiation, giving support to the adaptive value of robustness. Differences in robustness among the 2 viroid families can be explained by the larger fragility of branched structures compared with the rodlike ones. We also show that genomic redundancy can contribute to the robustness of these simple RNA genomes.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "8eceba755842479382ec48217193b107", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[0, 0], [86, 86]], "char_spans": [[0, 6], [499, 505]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["plant", 12], ["subviral", 18], ["pathogens", 27], ["whose", 37], ["genomes", 43], ["are", 51], ["constituted", 55], ["by", 67], ["a", 70], ["single", 72], ["-", 78], ["stranded", 79], ["and", 88], ["covalently", 92], ["closed", 103], ["small", 110], ["RNA", 116], ["molecule", 120], ["that", 129], ["does", 134], ["not", 139], ["encode", 143], ["for", 150], ["any", 154], ["protein", 158], [".", 165], ["Despite", 167], ["this", 175], ["genomic", 180], ["simplicity", 188], [",", 198], ["they", 200], ["are", 205], ["able", 209], ["of", 214], ["inducing", 217], ["devastating", 226], ["symptoms", 238], ["in", 247], ["susceptible", 250], ["plants", 262], [".", 268], ["Most", 270], ["of", 275], ["the", 278], ["29", 282], ["described", 285], ["viroid", 295], ["species", 302], ["fold", 310], ["into", 315], ["a", 320], ["rodlike", 322], ["or", 330], ["quasi", 333], ["-", 338], ["rodlike", 339], ["structure", 347], [",", 356], ["whereas", 358], ["a", 366], ["few", 368], ["of", 372], ["them", 375], ["fold", 380], ["as", 385], ["branched", 388], ["structures", 397], [".", 407], ["The", 409], ["shape", 413], ["of", 419], ["these", 422], ["RNA", 428], ["structures", 432], ["is", 443], ["perhaps", 446], ["one", 454], ["of", 458], ["the", 461], ["most", 465], ["characteristic", 470], ["properties", 485], ["of", 496], ["viroids", 499], ["and", 507], ["sometimes", 511], ["is", 521], ["considered", 524], ["their", 535], ["only", 541], ["phenotype", 546], [".", 555], ["Here", 557], ["we", 562], ["use", 565], ["RNA", 569], ["thermodynamic", 573], ["secondary", 587], ["structure", 597], ["prediction", 607], ["algorithms", 618], ["to", 629], ["compare", 632], ["the", 640], ["mutational", 644], ["robustness", 655], ["of", 666], ["all", 669], ["viroid", 673], ["species", 680], [".", 687], ["After", 689], ["characterizing", 695], ["the", 710], ["statistical", 714], ["properties", 726], ["of", 737], ["the", 740], ["distribution", 744], ["of", 757], ["mutational", 760], ["effects", 771], ["on", 779], ["structure", 782], ["stability", 792], ["and", 802], ["the", 806], ["wideness", 810], ["of", 819], ["neutral", 822], ["neighborhood", 830], ["for", 843], ["each", 847], ["viroid", 852], ["species", 859], [",", 866], ["we", 868], ["show", 871], ["an", 876], ["evolutionary", 879], ["trend", 892], ["toward", 898], ["increased", 905], ["structural", 915], ["robustness", 926], ["during", 937], ["viroid", 944], ["radiation", 951], [",", 960], ["giving", 962], ["support", 969], ["to", 977], ["the", 980], ["adaptive", 984], ["value", 993], ["of", 999], ["robustness", 1002], [".", 1012], ["Differences", 1014], ["in", 1026], ["robustness", 1029], ["among", 1040], ["the", 1046], ["2", 1050], ["viroid", 1052], ["families", 1059], ["can", 1068], ["be", 1072], ["explained", 1075], ["by", 1085], ["the", 1088], ["larger", 1092], ["fragility", 1099], ["of", 1109], ["branched", 1112], ["structures", 1121], ["compared", 1132], ["with", 1141], ["the", 1146], ["rodlike", 1150], ["ones", 1158], [".", 1162], ["We", 1164], ["also", 1167], ["show", 1172], ["that", 1177], ["genomic", 1182], ["redundancy", 1190], ["can", 1201], ["contribute", 1205], ["to", 1216], ["the", 1219], ["robustness", 1223], ["of", 1234], ["these", 1237], ["simple", 1243], ["RNA", 1250], ["genomes", 1254], [".", 1261]]}
{"context": "CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "3aa0a515baa742df87b15ccd76e1ea2d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[49, 49], [22, 22]], "char_spans": [[269, 276], [120, 127]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["a", 11], ["cerebrovascular", 13], ["disease", 29], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["NOTCH3", 64], ["gene", 71], [".", 75], ["Most", 77], ["mutations", 82], ["result", 92], ["in", 99], ["a", 102], ["gain", 104], ["or", 109], ["loss", 112], ["of", 117], ["cysteine", 120], ["residue", 129], ["in", 137], ["one", 140], ["of", 144], ["the", 147], ["34", 151], ["epidermal", 154], ["growth", 164], ["factor", 171], ["-", 177], ["like", 178], ["repeats", 183], ["in", 191], ["the", 194], ["extracellular", 198], ["domain", 212], ["of", 219], ["the", 222], ["Notch3", 226], ["protein", 233], [",", 240], ["thus", 242], ["sparing", 247], ["the", 255], ["number", 259], ["of", 266], ["cysteine", 269], ["residues", 278], [".", 286], ["To", 288], ["date", 291], [",", 295], ["more", 297], ["than", 302], ["130", 307], ["different", 311], ["mutations", 321], ["in", 331], ["the", 334], ["NOTCH3", 338], ["gene", 345], ["have", 350], ["been", 355], ["reported", 360], ["in", 369], ["CADASIL", 372], ["patients", 380], [",", 388], ["of", 390], ["which", 393], ["95", 399], ["%", 401], ["are", 403], ["missense", 407], ["point", 416], ["mutations", 422], [".", 431], ["Many", 433], ["polymorphisms", 438], ["have", 452], ["also", 457], ["been", 462], ["identified", 467], ["in", 478], ["the", 481], ["NOTCH3", 485], ["coding", 492], ["sequence", 499], [",", 507], ["some", 509], ["of", 514], ["them", 517], ["leading", 522], ["to", 530], ["amino", 533], ["acid", 539], ["substitutions", 544], [".", 557], ["The", 559], ["aim", 563], ["of", 567], ["the", 570], ["present", 574], ["study", 582], ["was", 588], ["to", 592], ["analyze", 595], ["the", 603], ["NOTCH3", 607], ["gene", 614], ["in", 619], ["a", 622], ["large", 624], ["group", 630], ["of", 636], ["patients", 639], ["affected", 648], ["by", 657], ["leukoencephalopathy", 660], ["and", 680], ["to", 684], ["investigate", 687], ["the", 699], ["presence", 703], ["of", 712], ["genetic", 715], ["variants", 723], [".", 731], ["The", 733], ["molecular", 737], ["analysis", 747], ["revealed", 756], ["several", 765], ["nucleotide", 773], ["alterations", 784], [".", 795], ["In", 797], ["particular", 800], [",", 810], ["we", 812], ["identified", 815], ["20", 826], ["different", 829], ["mutations", 839], [",", 848], ["22", 850], ["polymorphisms", 853], [",", 866], ["and", 868], ["8", 872], ["genetic", 874], ["variants", 882], ["of", 891], ["unknown", 894], ["pathological", 902], ["significance", 915], ["never", 928], ["reported", 934], ["previously", 943], [".", 953], ["We", 955], ["hope", 958], ["that", 963], ["this", 968], ["NOTCH3", 973], ["gene", 980], ["mutational", 985], ["analysis", 996], [",", 1004], ["performed", 1006], ["in", 1016], ["such", 1019], ["a", 1024], ["significant", 1026], ["number", 1038], ["of", 1045], ["unrelated", 1048], ["and", 1058], ["related", 1062], ["patients", 1070], ["affected", 1079], ["by", 1088], ["leukoencephalopathy", 1091], [",", 1110], ["will", 1112], ["help", 1117], ["in", 1122], ["molecular", 1125], ["screening", 1135], ["for", 1145], ["the", 1149], ["NOTCH3", 1153], ["gene", 1160], [",", 1164], ["thus", 1166], ["contributing", 1171], ["to", 1184], ["enlargement", 1187], ["of", 1199], ["the", 1202], ["NOTCH3", 1206], ["gene", 1213], ["variation", 1218], ["database", 1228], [".", 1236]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "4aa2254c611946849f987fbc7af289e2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[108, 110]], "char_spans": [[610, 627]]}]}], "context_tokens": [["Extrapolating", 0], ["the", 14], ["figures", 18], ["from", 26], ["a", 31], ["previous", 33], ["study", 42], ["on", 48], ["FSHD", 51], ["in", 56], ["a", 59], ["province", 61], ["of", 70], ["The", 73], ["Netherlands", 77], ["to", 89], ["the", 92], ["entire", 96], ["Dutch", 103], ["population", 109], ["suggests", 120], ["that", 129], ["at", 134], ["present", 137], ["a", 145], ["nearly", 147], ["complete", 154], ["overview", 163], ["is", 172], ["obtained", 175], ["of", 184], ["all", 187], ["symptomatic", 191], ["kindred", 203], [".", 210], ["In", 212], ["139", 215], ["families", 219], [",", 227], ["dominant", 229], ["inheritance", 238], ["was", 250], ["observed", 254], ["in", 263], ["97", 266], [",", 268], ["a", 270], ["pattern", 272], ["compatible", 280], ["with", 291], ["germline", 296], ["mosaicism", 305], ["in", 315], ["6", 318], [",", 319], ["while", 321], ["sporadic", 327], ["cases", 336], ["were", 342], ["found", 347], ["in", 353], ["36", 356], ["families", 359], [".", 367], ["A", 369], ["mutation", 371], ["frequency", 380], ["of", 390], ["9.6", 393], ["%", 396], ["was", 398], ["calculated", 402], [".", 412], ["Mental", 414], ["retardation", 421], ["and", 433], ["severe", 437], ["retinal", 444], ["vasculopathy", 452], ["were", 465], ["reported", 470], ["in", 479], ["low", 482], ["frequencies", 486], ["(", 498], ["1", 499], ["%", 500], [")", 501], [".", 502], ["Early", 504], ["onset", 510], ["was", 516], ["seen", 520], ["more", 525], ["frequently", 530], ["in", 541], ["sporadic", 544], ["cases", 553], [".", 558], ["Chromosome", 560], ["4", 571], ["linkage", 573], ["appeared", 581], ["excluded", 590], ["in", 599], ["3", 602], ["of", 604], ["22", 607], ["autosomal", 610], ["-", 619], ["dominant", 620], ["families", 629], [".", 637], ["The", 639], ["clinical", 643], ["pictures", 652], ["in", 661], ["the", 664], ["linked", 668], ["and", 675], ["nonlinked", 679], ["families", 689], ["were", 698], ["identical", 703], [".", 712]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "The serotonergic system is implicated in the pathophysiology of posttraumatic stress disorder (PTSD) and depression. The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD. PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale. Sixty-five male drug-free war veterans (48 with PTSD and 17 without PTSD) and 65 age- and sex-matched healthy controls were studied. Comorbid depression occurred in 54 and 31% of war veterans with PTSD and without PTSD, respectively. Platelet 5-HT concentration was similar in the groups of depressed and nondepressed war veterans with or without PTSD and healthy controls. Platelet 5-HT concentration was found to differ between war veterans with various degrees of appetite loss. A positive correlation was observed between platelet 5-HT concentration and severity of appetite loss in veterans with PTSD. There was no relationship between platelet 5-HT concentration and severity of other symptoms of PTSD or depression. War veterans included in the study were outpatients. War veterans with PTSD had a high incidence of comorbid depression, that was not related to platelet 5-HT concentration. The marked relationship between platelet 5-HT concentration and severity of appetite loss, suggested that 5-HT system is involved in the regulation of appetite, at least in depressed war veterans with PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "3a4f863ee8e149ab960b2f0eccb04cdd", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[80, 80], [13, 13], [173, 173], [42, 42], [134, 134], [189, 189], [205, 205], [84, 84], [40, 40], [255, 255], [50, 50], [113, 113], [110, 110]], "char_spans": [[477, 480], [95, 98], [1030, 1033], [260, 263], [776, 779], [1132, 1135], [1223, 1226], [497, 500], [254, 257], [1527, 1530], [324, 327], [643, 646], [626, 629]]}]}], "context_tokens": [["The", 0], ["serotonergic", 4], ["system", 17], ["is", 24], ["implicated", 27], ["in", 38], ["the", 41], ["pathophysiology", 45], ["of", 61], ["posttraumatic", 64], ["stress", 78], ["disorder", 85], ["(", 94], ["PTSD", 95], [")", 99], ["and", 101], ["depression", 105], [".", 115], ["The", 117], ["present", 121], ["study", 129], ["focused", 135], ["on", 143], ["platelet", 146], ["serotonin", 155], ["(", 165], ["5-HT", 166], [")", 170], ["concentration", 172], ["and", 186], ["symptoms", 190], ["of", 199], ["comorbid", 202], ["depression", 211], ["in", 222], ["war", 225], ["veterans", 229], ["with", 238], ["or", 243], ["without", 246], ["PTSD", 254], [".", 258], ["PTSD", 260], ["and", 265], ["depression", 269], ["were", 280], ["evaluated", 285], ["using", 295], ["Clinician", 301], ["Administered", 311], ["PTSD", 324], ["Scale", 329], [",", 334], ["Davidson", 336], ["Trauma", 345], ["Scale", 352], [",", 357], ["Montgomery", 359], ["-", 369], ["Asberg", 370], ["Depression", 377], ["Rating", 388], ["Scale", 395], ["and", 401], ["Hamilton", 405], ["Anxiety", 414], ["Scale", 422], [".", 427], ["Sixty", 429], ["-", 434], ["five", 435], ["male", 440], ["drug", 445], ["-", 449], ["free", 450], ["war", 455], ["veterans", 459], ["(", 468], ["48", 469], ["with", 472], ["PTSD", 477], ["and", 482], ["17", 486], ["without", 489], ["PTSD", 497], [")", 501], ["and", 503], ["65", 507], ["age-", 510], ["and", 515], ["sex", 519], ["-", 522], ["matched", 523], ["healthy", 531], ["controls", 539], ["were", 548], ["studied", 553], [".", 560], ["Comorbid", 562], ["depression", 571], ["occurred", 582], ["in", 591], ["54", 594], ["and", 597], ["31", 601], ["%", 603], ["of", 605], ["war", 608], ["veterans", 612], ["with", 621], ["PTSD", 626], ["and", 631], ["without", 635], ["PTSD", 643], [",", 647], ["respectively", 649], [".", 661], ["Platelet", 663], ["5-HT", 672], ["concentration", 677], ["was", 691], ["similar", 695], ["in", 703], ["the", 706], ["groups", 710], ["of", 717], ["depressed", 720], ["and", 730], ["nondepressed", 734], ["war", 747], ["veterans", 751], ["with", 760], ["or", 765], ["without", 768], ["PTSD", 776], ["and", 781], ["healthy", 785], ["controls", 793], [".", 801], ["Platelet", 803], ["5-HT", 812], ["concentration", 817], ["was", 831], ["found", 835], ["to", 841], ["differ", 844], ["between", 851], ["war", 859], ["veterans", 863], ["with", 872], ["various", 877], ["degrees", 885], ["of", 893], ["appetite", 896], ["loss", 905], [".", 909], ["A", 911], ["positive", 913], ["correlation", 922], ["was", 934], ["observed", 938], ["between", 947], ["platelet", 955], ["5-HT", 964], ["concentration", 969], ["and", 983], ["severity", 987], ["of", 996], ["appetite", 999], ["loss", 1008], ["in", 1013], ["veterans", 1016], ["with", 1025], ["PTSD", 1030], [".", 1034], ["There", 1036], ["was", 1042], ["no", 1046], ["relationship", 1049], ["between", 1062], ["platelet", 1070], ["5-HT", 1079], ["concentration", 1084], ["and", 1098], ["severity", 1102], ["of", 1111], ["other", 1114], ["symptoms", 1120], ["of", 1129], ["PTSD", 1132], ["or", 1137], ["depression", 1140], [".", 1150], ["War", 1152], ["veterans", 1156], ["included", 1165], ["in", 1174], ["the", 1177], ["study", 1181], ["were", 1187], ["outpatients", 1192], [".", 1203], ["War", 1205], ["veterans", 1209], ["with", 1218], ["PTSD", 1223], ["had", 1228], ["a", 1232], ["high", 1234], ["incidence", 1239], ["of", 1249], ["comorbid", 1252], ["depression", 1261], [",", 1271], ["that", 1273], ["was", 1278], ["not", 1282], ["related", 1286], ["to", 1294], ["platelet", 1297], ["5-HT", 1306], ["concentration", 1311], [".", 1324], ["The", 1326], ["marked", 1330], ["relationship", 1337], ["between", 1350], ["platelet", 1358], ["5-HT", 1367], ["concentration", 1372], ["and", 1386], ["severity", 1390], ["of", 1399], ["appetite", 1402], ["loss", 1411], [",", 1415], ["suggested", 1417], ["that", 1427], ["5-HT", 1432], ["system", 1437], ["is", 1444], ["involved", 1447], ["in", 1456], ["the", 1459], ["regulation", 1463], ["of", 1474], ["appetite", 1477], [",", 1485], ["at", 1487], ["least", 1490], ["in", 1496], ["depressed", 1499], ["war", 1509], ["veterans", 1513], ["with", 1522], ["PTSD", 1527], [".", 1531]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. Cardiac abnormalities, such as aortic root dilation have also been noted as well as several skeletal abnormalities. Its nosological status is unclear as it is hard to delineate SGS from similar disorders, such as Furlong, Marfan type II, Camurati-Engelmann and Loeys-Dietz syndromes. It has been suggested that these conditions represent a phenotypical spectrum associated with aberrant TGF-beta signalling. In support of this notion, we found a novel TGFBR2 missense mutation in a patient with features of SGS.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "9038f03f7233434d94806443d485149a", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[22, 22]], "char_spans": [[117, 132]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["a", 38], ["rare", 40], ["disorder", 45], ["characterized", 54], ["by", 68], ["a", 71], ["Marfan", 73], ["-", 79], ["like", 80], ["habitus", 85], [",", 92], ["mental", 94], ["retardation", 101], ["and", 113], ["craniosynostosis", 117], [".", 133], ["Cardiac", 135], ["abnormalities", 143], [",", 156], ["such", 158], ["as", 163], ["aortic", 166], ["root", 173], ["dilation", 178], ["have", 187], ["also", 192], ["been", 197], ["noted", 202], ["as", 208], ["well", 211], ["as", 216], ["several", 219], ["skeletal", 227], ["abnormalities", 236], [".", 249], ["Its", 251], ["nosological", 255], ["status", 267], ["is", 274], ["unclear", 277], ["as", 285], ["it", 288], ["is", 291], ["hard", 294], ["to", 299], ["delineate", 302], ["SGS", 312], ["from", 316], ["similar", 321], ["disorders", 329], [",", 338], ["such", 340], ["as", 345], ["Furlong", 348], [",", 355], ["Marfan", 357], ["type", 364], ["II", 369], [",", 371], ["Camurati", 373], ["-", 381], ["Engelmann", 382], ["and", 392], ["Loeys", 396], ["-", 401], ["Dietz", 402], ["syndromes", 408], [".", 417], ["It", 419], ["has", 422], ["been", 426], ["suggested", 431], ["that", 441], ["these", 446], ["conditions", 452], ["represent", 463], ["a", 473], ["phenotypical", 475], ["spectrum", 488], ["associated", 497], ["with", 508], ["aberrant", 513], ["TGF", 522], ["-", 525], ["beta", 526], ["signalling", 531], [".", 541], ["In", 543], ["support", 546], ["of", 554], ["this", 557], ["notion", 562], [",", 568], ["we", 570], ["found", 573], ["a", 579], ["novel", 581], ["TGFBR2", 587], ["missense", 594], ["mutation", 603], ["in", 612], ["a", 615], ["patient", 617], ["with", 625], ["features", 630], ["of", 639], ["SGS", 642], [".", 645]]}
{"context": "The inflammatory cytokine IL-1\u03b2 has an essential role in the innate immune response. High levels of IL-1\u03b2 have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1\u03b2, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1\u03b2 and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Beh\u00e7et's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "e156bae24ed442c581112e4b34e212a5", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[17, 17], [63, 63], [3, 3], [79, 79]], "char_spans": [[100, 104], [344, 348], [26, 30], [434, 438]]}]}], "context_tokens": [["The", 0], ["inflammatory", 4], ["cytokine", 17], ["IL-1\u03b2", 26], ["has", 32], ["an", 36], ["essential", 39], ["role", 49], ["in", 54], ["the", 57], ["innate", 61], ["immune", 68], ["response", 75], [".", 83], ["High", 85], ["levels", 90], ["of", 97], ["IL-1\u03b2", 100], ["have", 106], ["been", 111], ["implicated", 116], ["in", 127], ["the", 130], ["development", 134], ["of", 146], ["many", 149], ["diseases", 154], [",", 162], ["including", 164], ["type", 174], ["1", 179], ["and", 181], ["2", 185], ["diabetes", 187], ["(", 196], ["T1D", 197], ["and", 201], ["T2D", 205], [")", 208], [",", 209], ["rheumatoid", 211], ["arthritis", 222], ["(", 232], ["RA", 233], [")", 235], ["and", 237], ["cardiovascular", 241], ["disease", 256], [".", 263], ["XOMA", 265], ["is", 270], ["developing", 273], ["gevokizumab", 284], ["(", 296], ["XOMA-052", 297], [")", 305], [",", 306], ["an", 308], ["IgG2", 311], ["humanized", 316], ["mAb", 326], ["against", 330], ["human", 338], ["IL-1\u03b2", 344], [",", 349], ["for", 351], ["the", 355], ["potential", 359], ["treatment", 369], ["of", 379], ["these", 382], ["diseases", 388], [".", 396], ["Gevokizumab", 398], ["has", 410], ["a", 414], ["high", 416], ["affinity", 421], ["for", 430], ["IL-1\u03b2", 434], ["and", 440], ["a", 444], ["long", 446], ["t1/2", 451], [",", 455], ["which", 457], ["would", 463], ["allow", 469], ["for", 475], ["once", 479], ["-", 483], ["monthly", 484], ["dosing", 492], ["and", 499], ["offer", 503], ["a", 509], ["considerable", 511], ["advantage", 524], ["for", 534], ["patients", 538], ["over", 547], ["agents", 552], ["requiring", 559], ["more", 569], ["frequent", 574], ["dosing", 583], [".", 589], ["Data", 591], ["from", 596], ["preclinical", 601], ["studies", 613], ["and", 621], ["clinical", 625], ["trials", 634], ["suggest", 641], ["that", 649], ["gevokizumab", 654], ["is", 666], ["a", 669], ["potentially", 671], ["effective", 683], ["and", 693], ["well", 697], ["-", 701], ["tolerated", 702], ["treatment", 712], ["for", 722], ["the", 726], ["indicated", 730], ["diseases", 740], [".", 748], ["At", 750], ["the", 753], ["time", 757], ["of", 762], ["publication", 765], [",", 776], ["phase", 778], ["II", 784], ["clinical", 787], ["trials", 796], ["were", 803], ["ongoing", 808], ["in", 816], ["patients", 819], ["with", 828], ["T1D", 833], [",", 836], ["T2D", 838], ["and", 842], ["RA", 846], [",", 848], ["with", 850], ["the", 855], ["T2D", 859], ["trials", 863], ["assessing", 870], ["key", 880], ["cardiovascular", 884], ["markers", 899], [".", 906], ["Following", 908], ["promising", 918], ["data", 928], ["from", 933], ["a", 938], ["recent", 940], ["pilot", 947], ["trial", 953], [",", 958], ["XOMA", 960], ["was", 965], ["also", 969], ["planning", 974], ["a", 983], ["phase", 985], ["I", 991], ["/", 992], ["II", 993], ["trial", 996], ["of", 1002], ["gevokizumab", 1005], ["for", 1017], ["the", 1021], ["potential", 1025], ["treatment", 1035], ["of", 1045], ["uveitis", 1048], ["in", 1056], ["patients", 1059], ["with", 1068], ["the", 1073], ["vasculitic", 1077], ["inflammatory", 1088], ["disorder", 1101], ["Beh\u00e7et", 1110], ["'s", 1116], ["disease", 1119], ["and", 1127], ["the", 1131], ["autoinflammatory", 1135], ["conditions", 1152], ["familial", 1163], ["cold", 1172], ["autoinflammatory", 1177], ["syndrome", 1194], ["and", 1203], ["Muckle", 1207], ["-", 1213], ["Wells", 1214], ["syndrome", 1220], [".", 1228]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are already available in many countries (dapagliflozin, canagliflozin, empagliflozin and ipragliflozin) and some others are in a late phase of development. The available SGLT2 inhibitors share similar pharmacokinetic characteristics, with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites, the absence of clinically relevant drug-drug interactions and a low renal elimination as parent drug. SGLT2 co-transporters are responsible for reabsorption of most (90\u00a0%) of the glucose filtered by the kidneys. The pharmacological inhibition of SGLT2 co-transporters reduces hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. The amount of glucose excreted in the urine depends on both the level of hyperglycaemia and the glomerular filtration rate. Results of numerous placebo-controlled randomised clinical trials of 12-104\u00a0weeks duration have shown significant reductions in glycated haemoglobin (HbA1c), resulting in a significant increase in the proportion of patients reaching HbA1c targets, and a significant lowering of fasting plasma glucose when SGLT2 inhibitors were administered as monotherapy or in addition to other glucose-lowering therapies including insulin in patients with T2DM. In head-to-head trials of up to 2\u00a0years, SGLT2 inhibitors exerted similar glucose-lowering activity to metformin, sulphonylureas or sitagliptin. The durability of the glucose-lowering effect of SGLT2 inhibitors appears to be better; however, this remains to be more extensively investigated. The risk of hypoglycaemia was much lower with SGLT2 inhibitors than with sulphonylureas and was similarly low as that reported with metformin, pioglitazone or sitagliptin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Both effects were very consistent across the trials and they represent some advantages for SGLT2 inhibitors when compared with other oral glucose-lowering agents. The pharmacodynamic response to SGLT2 inhibitors declines with increasing severity of renal impairment, and prescribing information for each SGLT2 inhibitor should be consulted regarding dosage adjustments or restrictions in moderate to severe renal dysfunction. Caution is also recommended in the elderly population because of a higher risk of renal impairment, orthostatic hypotension and dehydration, even if the absence of hypoglycaemia represents an obvious advantage in this population. The overall effect of SGLT2 inhibitors on the risk of cardiovascular disease is unknown and will be evaluated in several ongoing prospective placebo-controlled trials with cardiovascular outcomes. The impact of SGLT2 inhibitors on renal function and their potential to influence the course of diabetic nephropathy also deserve more attention. SGLT2 inhibitors are generally well-tolerated. The most frequently reported adverse events are female genital mycotic infections, while urinary tract infections are less commonly observed and generally benign. In conclusion, with their unique mechanism of action that is independent of insulin secretion and action, SGLT2 inhibitors are a useful addition to the therapeutic options available for the management of T2DM at any stage in the natural history of the disease. Although SGLT2 inhibitors have already been extensively investigated, further studies should even better delineate the best place of these new glucose-lowering agents in the already rich armamentarium for the management of T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "32d5c9e48b75450989842a6e97cc6f21", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[288, 288], [229, 229], [141, 141], [11, 11], [115, 115], [61, 61], [362, 362], [378, 378], [499, 499], [313, 313], [393, 393], [577, 577], [549, 549], [264, 264], [450, 450], [479, 479]], "char_spans": [[1723, 1727], [1387, 1391], [824, 828], [52, 56], [680, 684], [335, 339], [2186, 2190], [2290, 2294], [3094, 3098], [1867, 1871], [2399, 2403], [3574, 3578], [3410, 3414], [1570, 1574], [2773, 2777], [2962, 2966]]}]}], "context_tokens": [["Inhibitors", 0], ["of", 11], ["sodium", 14], ["-", 20], ["glucose", 21], ["co", 29], ["-", 31], ["transporter", 32], ["type", 44], ["2", 49], ["(", 51], ["SGLT2", 52], [")", 57], ["are", 59], ["proposed", 63], ["as", 72], ["a", 75], ["novel", 77], ["approach", 83], ["for", 92], ["the", 96], ["management", 100], ["of", 111], ["type", 114], ["2", 119], ["diabetes", 121], ["mellitus", 130], ["(", 139], ["T2DM", 140], [")", 144], [".", 145], ["Several", 147], ["compounds", 155], ["are", 165], ["already", 169], ["available", 177], ["in", 187], ["many", 190], ["countries", 195], ["(", 205], ["dapagliflozin", 206], [",", 219], ["canagliflozin", 221], [",", 234], ["empagliflozin", 236], ["and", 250], ["ipragliflozin", 254], [")", 267], ["and", 269], ["some", 273], ["others", 278], ["are", 285], ["in", 289], ["a", 292], ["late", 294], ["phase", 299], ["of", 305], ["development", 308], [".", 319], ["The", 321], ["available", 325], ["SGLT2", 335], ["inhibitors", 341], ["share", 352], ["similar", 358], ["pharmacokinetic", 366], ["characteristics", 382], [",", 397], ["with", 399], ["a", 404], ["rapid", 406], ["oral", 412], ["absorption", 417], [",", 427], ["a", 429], ["long", 431], ["elimination", 436], ["half", 448], ["-", 452], ["life", 453], ["allowing", 458], ["once", 467], ["-", 471], ["daily", 472], ["administration", 478], [",", 492], ["an", 494], ["extensive", 497], ["hepatic", 507], ["metabolism", 515], ["mainly", 526], ["via", 533], ["glucuronidation", 537], ["to", 553], ["inactive", 556], ["metabolites", 565], [",", 576], ["the", 578], ["absence", 582], ["of", 590], ["clinically", 593], ["relevant", 604], ["drug", 613], ["-", 617], ["drug", 618], ["interactions", 623], ["and", 636], ["a", 640], ["low", 642], ["renal", 646], ["elimination", 652], ["as", 664], ["parent", 667], ["drug", 674], [".", 678], ["SGLT2", 680], ["co", 686], ["-", 688], ["transporters", 689], ["are", 702], ["responsible", 706], ["for", 718], ["reabsorption", 722], ["of", 735], ["most", 738], ["(", 743], ["90", 744], ["%", 747], [")", 748], ["of", 750], ["the", 753], ["glucose", 757], ["filtered", 765], ["by", 774], ["the", 777], ["kidneys", 781], [".", 788], ["The", 790], ["pharmacological", 794], ["inhibition", 810], ["of", 821], ["SGLT2", 824], ["co", 830], ["-", 832], ["transporters", 833], ["reduces", 846], ["hyperglycaemia", 854], ["by", 869], ["decreasing", 872], ["renal", 883], ["glucose", 889], ["threshold", 897], ["and", 907], ["thereby", 911], ["increasing", 919], ["urinary", 930], ["glucose", 938], ["excretion", 946], [".", 955], ["The", 957], ["amount", 961], ["of", 968], ["glucose", 971], ["excreted", 979], ["in", 988], ["the", 991], ["urine", 995], ["depends", 1001], ["on", 1009], ["both", 1012], ["the", 1017], ["level", 1021], ["of", 1027], ["hyperglycaemia", 1030], ["and", 1045], ["the", 1049], ["glomerular", 1053], ["filtration", 1064], ["rate", 1075], [".", 1079], ["Results", 1081], ["of", 1089], ["numerous", 1092], ["placebo", 1101], ["-", 1108], ["controlled", 1109], ["randomised", 1120], ["clinical", 1131], ["trials", 1140], ["of", 1147], ["12", 1150], ["-", 1152], ["104", 1153], ["weeks", 1157], ["duration", 1163], ["have", 1172], ["shown", 1177], ["significant", 1183], ["reductions", 1195], ["in", 1206], ["glycated", 1209], ["haemoglobin", 1218], ["(", 1230], ["HbA1c", 1231], [")", 1236], [",", 1237], ["resulting", 1239], ["in", 1249], ["a", 1252], ["significant", 1254], ["increase", 1266], ["in", 1275], ["the", 1278], ["proportion", 1282], ["of", 1293], ["patients", 1296], ["reaching", 1305], ["HbA1c", 1314], ["targets", 1320], [",", 1327], ["and", 1329], ["a", 1333], ["significant", 1335], ["lowering", 1347], ["of", 1356], ["fasting", 1359], ["plasma", 1367], ["glucose", 1374], ["when", 1382], ["SGLT2", 1387], ["inhibitors", 1393], ["were", 1404], ["administered", 1409], ["as", 1422], ["monotherapy", 1425], ["or", 1437], ["in", 1440], ["addition", 1443], ["to", 1452], ["other", 1455], ["glucose", 1461], ["-", 1468], ["lowering", 1469], ["therapies", 1478], ["including", 1488], ["insulin", 1498], ["in", 1506], ["patients", 1509], ["with", 1518], ["T2DM", 1523], [".", 1527], ["In", 1529], ["head", 1532], ["-", 1536], ["to", 1537], ["-", 1539], ["head", 1540], ["trials", 1545], ["of", 1552], ["up", 1555], ["to", 1558], ["2", 1561], ["years", 1563], [",", 1568], ["SGLT2", 1570], ["inhibitors", 1576], ["exerted", 1587], ["similar", 1595], ["glucose", 1603], ["-", 1610], ["lowering", 1611], ["activity", 1620], ["to", 1629], ["metformin", 1632], [",", 1641], ["sulphonylureas", 1643], ["or", 1658], ["sitagliptin", 1661], [".", 1672], ["The", 1674], ["durability", 1678], ["of", 1689], ["the", 1692], ["glucose", 1696], ["-", 1703], ["lowering", 1704], ["effect", 1713], ["of", 1720], ["SGLT2", 1723], ["inhibitors", 1729], ["appears", 1740], ["to", 1748], ["be", 1751], ["better", 1754], [";", 1760], ["however", 1762], [",", 1769], ["this", 1771], ["remains", 1776], ["to", 1784], ["be", 1787], ["more", 1790], ["extensively", 1795], ["investigated", 1807], [".", 1819], ["The", 1821], ["risk", 1825], ["of", 1830], ["hypoglycaemia", 1833], ["was", 1847], ["much", 1851], ["lower", 1856], ["with", 1862], ["SGLT2", 1867], ["inhibitors", 1873], ["than", 1884], ["with", 1889], ["sulphonylureas", 1894], ["and", 1909], ["was", 1913], ["similarly", 1917], ["low", 1927], ["as", 1931], ["that", 1934], ["reported", 1939], ["with", 1948], ["metformin", 1953], [",", 1962], ["pioglitazone", 1964], ["or", 1977], ["sitagliptin", 1980], [".", 1991], ["Increased", 1993], ["renal", 2003], ["glucose", 2009], ["elimination", 2017], ["also", 2029], ["assists", 2034], ["weight", 2042], ["loss", 2049], ["and", 2054], ["could", 2058], ["help", 2064], ["to", 2069], ["reduce", 2072], ["blood", 2079], ["pressure", 2085], [".", 2093], ["Both", 2095], ["effects", 2100], ["were", 2108], ["very", 2113], ["consistent", 2118], ["across", 2129], ["the", 2136], ["trials", 2140], ["and", 2147], ["they", 2151], ["represent", 2156], ["some", 2166], ["advantages", 2171], ["for", 2182], ["SGLT2", 2186], ["inhibitors", 2192], ["when", 2203], ["compared", 2208], ["with", 2217], ["other", 2222], ["oral", 2228], ["glucose", 2233], ["-", 2240], ["lowering", 2241], ["agents", 2250], [".", 2256], ["The", 2258], ["pharmacodynamic", 2262], ["response", 2278], ["to", 2287], ["SGLT2", 2290], ["inhibitors", 2296], ["declines", 2307], ["with", 2316], ["increasing", 2321], ["severity", 2332], ["of", 2341], ["renal", 2344], ["impairment", 2350], [",", 2360], ["and", 2362], ["prescribing", 2366], ["information", 2378], ["for", 2390], ["each", 2394], ["SGLT2", 2399], ["inhibitor", 2405], ["should", 2415], ["be", 2422], ["consulted", 2425], ["regarding", 2435], ["dosage", 2445], ["adjustments", 2452], ["or", 2464], ["restrictions", 2467], ["in", 2480], ["moderate", 2483], ["to", 2492], ["severe", 2495], ["renal", 2502], ["dysfunction", 2508], [".", 2519], ["Caution", 2521], ["is", 2529], ["also", 2532], ["recommended", 2537], ["in", 2549], ["the", 2552], ["elderly", 2556], ["population", 2564], ["because", 2575], ["of", 2583], ["a", 2586], ["higher", 2588], ["risk", 2595], ["of", 2600], ["renal", 2603], ["impairment", 2609], [",", 2619], ["orthostatic", 2621], ["hypotension", 2633], ["and", 2645], ["dehydration", 2649], [",", 2660], ["even", 2662], ["if", 2667], ["the", 2670], ["absence", 2674], ["of", 2682], ["hypoglycaemia", 2685], ["represents", 2699], ["an", 2710], ["obvious", 2713], ["advantage", 2721], ["in", 2731], ["this", 2734], ["population", 2739], [".", 2749], ["The", 2751], ["overall", 2755], ["effect", 2763], ["of", 2770], ["SGLT2", 2773], ["inhibitors", 2779], ["on", 2790], ["the", 2793], ["risk", 2797], ["of", 2802], ["cardiovascular", 2805], ["disease", 2820], ["is", 2828], ["unknown", 2831], ["and", 2839], ["will", 2843], ["be", 2848], ["evaluated", 2851], ["in", 2861], ["several", 2864], ["ongoing", 2872], ["prospective", 2880], ["placebo", 2892], ["-", 2899], ["controlled", 2900], ["trials", 2911], ["with", 2918], ["cardiovascular", 2923], ["outcomes", 2938], [".", 2946], ["The", 2948], ["impact", 2952], ["of", 2959], ["SGLT2", 2962], ["inhibitors", 2968], ["on", 2979], ["renal", 2982], ["function", 2988], ["and", 2997], ["their", 3001], ["potential", 3007], ["to", 3017], ["influence", 3020], ["the", 3030], ["course", 3034], ["of", 3041], ["diabetic", 3044], ["nephropathy", 3053], ["also", 3065], ["deserve", 3070], ["more", 3078], ["attention", 3083], [".", 3092], ["SGLT2", 3094], ["inhibitors", 3100], ["are", 3111], ["generally", 3115], ["well", 3125], ["-", 3129], ["tolerated", 3130], [".", 3139], ["The", 3141], ["most", 3145], ["frequently", 3150], ["reported", 3161], ["adverse", 3170], ["events", 3178], ["are", 3185], ["female", 3189], ["genital", 3196], ["mycotic", 3204], ["infections", 3212], [",", 3222], ["while", 3224], ["urinary", 3230], ["tract", 3238], ["infections", 3244], ["are", 3255], ["less", 3259], ["commonly", 3264], ["observed", 3273], ["and", 3282], ["generally", 3286], ["benign", 3296], [".", 3302], ["In", 3304], ["conclusion", 3307], [",", 3317], ["with", 3319], ["their", 3324], ["unique", 3330], ["mechanism", 3337], ["of", 3347], ["action", 3350], ["that", 3357], ["is", 3362], ["independent", 3365], ["of", 3377], ["insulin", 3380], ["secretion", 3388], ["and", 3398], ["action", 3402], [",", 3408], ["SGLT2", 3410], ["inhibitors", 3416], ["are", 3427], ["a", 3431], ["useful", 3433], ["addition", 3440], ["to", 3449], ["the", 3452], ["therapeutic", 3456], ["options", 3468], ["available", 3476], ["for", 3486], ["the", 3490], ["management", 3494], ["of", 3505], ["T2DM", 3508], ["at", 3513], ["any", 3516], ["stage", 3520], ["in", 3526], ["the", 3529], ["natural", 3533], ["history", 3541], ["of", 3549], ["the", 3552], ["disease", 3556], [".", 3563], ["Although", 3565], ["SGLT2", 3574], ["inhibitors", 3580], ["have", 3591], ["already", 3596], ["been", 3604], ["extensively", 3609], ["investigated", 3621], [",", 3633], ["further", 3635], ["studies", 3643], ["should", 3651], ["even", 3658], ["better", 3663], ["delineate", 3670], ["the", 3680], ["best", 3684], ["place", 3689], ["of", 3695], ["these", 3698], ["new", 3704], ["glucose", 3708], ["-", 3715], ["lowering", 3716], ["agents", 3725], ["in", 3732], ["the", 3735], ["already", 3739], ["rich", 3747], ["armamentarium", 3752], ["for", 3766], ["the", 3770], ["management", 3774], ["of", 3785], ["T2DM", 3788], [".", 3792]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. From March 27, 2009, until Jan 31, 2011, children (age 5-17 months) and young infants (age 6-12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical malaria was analysed by negative binomial regression and against severe malaria by relative risk reduction. This trial is registered with ClinicalTrials.gov, number NCT00866619. 8922 children and 6537 young infants were included in the modified intention-to-treat analyses. Children were followed up for a median of 48 months (IQR 39-50) and young infants for 38 months (34-41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C group, 6616 episodes occurred in the R3R group (VE 36\u00b73%, 95% CI 31\u00b78-40\u00b75) and 7396 occurred in the R3C group (28\u00b73%, 23\u00b73-32\u00b79); compared with 171 children who experienced at least one episode of severe malaria in the C3C group, 116 children experienced at least one episode of severe malaria in the R3R group (32\u00b72%, 13\u00b77 to 46\u00b79) and 169 in the R3C group (1\u00b71%, -23\u00b70 to 20\u00b75). In young infants, compared with 6170 episodes of clinical malaria that met the primary case definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25\u00b79%, 95% CI 19\u00b79-31\u00b75) and 5444 occurred in the R3C group (18\u00b73%, 11\u00b77-24\u00b74); and compared with 116 infants who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced at least one episode of severe malaria in the R3R group (17\u00b73%, 95% CI -9\u00b74 to 37\u00b75) and 104 in the R3C group (10\u00b73%, -17\u00b79 to 31\u00b78). In children, 1774 cases of clinical malaria were averted per 1000 children (95% CI 1387-2186) in the R3R group and 1363 per 1000 children (995-1797) in the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592-1337) in the R3R group and 558 (158-926) in the R3C group. The frequency of SAEs overall was balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\u00b72 per 1000 doses in young infants and 2\u00b75 per 1000 doses in children. RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e339e78113964de2b3b0f21b5a8d959d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[261, 261], [419, 419], [358, 358], [547, 547], [739, 739], [789, 789], [196, 196], [12, 12], [231, 231], [434, 434], [532, 532], [585, 585], [280, 280], [472, 472], [270, 270]], "char_spans": [[1217, 1223], [2000, 2006], [1727, 1733], [2579, 2585], [3391, 3397], [3662, 3668], [857, 863], [52, 58], [1066, 1072], [2082, 2088], [2499, 2505], [2718, 2724], [1337, 1343], [2235, 2241], [1265, 1271]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["the", 27], ["RTS", 31], [",", 34], ["S", 35], ["/", 36], ["AS01", 37], ["candidate", 42], ["malaria", 52], ["vaccine", 60], ["during", 68], ["18", 75], ["months", 78], ["of", 85], ["follow", 88], ["-", 94], ["up", 95], ["have", 98], ["been", 103], ["published", 108], ["previously", 118], [".", 128], ["Herein", 130], [",", 136], ["we", 138], ["report", 141], ["the", 148], ["final", 152], ["results", 158], ["from", 166], ["the", 171], ["same", 175], ["trial", 180], [",", 185], ["including", 187], ["the", 197], ["efficacy", 201], ["of", 210], ["a", 213], ["booster", 215], ["dose", 223], [".", 227], ["From", 229], ["March", 234], ["27", 240], [",", 242], ["2009", 244], [",", 248], ["until", 250], ["Jan", 256], ["31", 260], [",", 262], ["2011", 264], [",", 268], ["children", 270], ["(", 279], ["age", 280], ["5", 284], ["-", 285], ["17", 286], ["months", 289], [")", 295], ["and", 297], ["young", 301], ["infants", 307], ["(", 315], ["age", 316], ["6", 320], ["-", 321], ["12", 322], ["weeks", 325], [")", 330], ["were", 332], ["enrolled", 337], ["at", 346], ["11", 349], ["centres", 352], ["in", 360], ["seven", 363], ["countries", 369], ["in", 379], ["sub", 382], ["-", 385], ["Saharan", 386], ["Africa", 394], [".", 400], ["Participants", 402], ["were", 415], ["randomly", 420], ["assigned", 429], ["(", 438], ["1:1:1", 439], [")", 444], ["at", 446], ["first", 449], ["vaccination", 455], ["by", 467], ["block", 470], ["randomisation", 476], ["with", 490], ["minimisation", 495], ["by", 508], ["centre", 511], ["to", 518], ["receive", 521], ["three", 529], ["doses", 535], ["of", 541], ["RTS", 544], [",", 547], ["S", 548], ["/", 549], ["AS01", 550], ["at", 555], ["months", 558], ["0", 565], [",", 566], ["1", 568], [",", 569], ["and", 571], ["2", 575], ["and", 577], ["a", 581], ["booster", 583], ["dose", 591], ["at", 596], ["month", 599], ["20", 605], ["(", 608], ["R3R", 609], ["group", 613], [")", 618], [";", 619], ["three", 621], ["doses", 627], ["of", 633], ["RTS", 636], [",", 639], ["S", 640], ["/", 641], ["AS01", 642], ["and", 647], ["a", 651], ["dose", 653], ["of", 658], ["comparator", 661], ["vaccine", 672], ["at", 680], ["month", 683], ["20", 689], ["(", 692], ["R3C", 693], ["group", 697], [")", 702], [";", 703], ["or", 705], ["a", 708], ["comparator", 710], ["vaccine", 721], ["at", 729], ["months", 732], ["0", 739], [",", 740], ["1", 742], [",", 743], ["2", 745], [",", 746], ["and", 748], ["20", 752], ["(", 755], ["C3C", 756], ["[", 760], ["control", 761], ["group", 769], ["]", 774], [")", 775], [".", 776], ["Participants", 778], ["were", 791], ["followed", 796], ["up", 805], ["until", 808], ["Jan", 814], ["31", 818], [",", 820], ["2014", 822], [".", 826], ["Cases", 828], ["of", 834], ["clinical", 837], ["and", 846], ["severe", 850], ["malaria", 857], ["were", 865], ["captured", 870], ["through", 879], ["passive", 887], ["case", 895], ["detection", 900], [".", 909], ["Serious", 911], ["adverse", 919], ["events", 927], ["(", 934], ["SAEs", 935], [")", 939], ["were", 941], ["recorded", 946], [".", 954], ["Analyses", 956], ["were", 965], ["by", 970], ["modified", 973], ["intention", 982], ["to", 992], ["treat", 995], ["and", 1001], ["per", 1005], ["protocol", 1009], [".", 1017], ["The", 1019], ["coprimary", 1023], ["endpoints", 1033], ["were", 1043], ["the", 1048], ["occurrence", 1052], ["of", 1063], ["malaria", 1066], ["over", 1074], ["12", 1079], ["months", 1082], ["after", 1089], ["dose", 1095], ["3", 1100], ["in", 1102], ["each", 1105], ["age", 1110], ["category", 1114], [".", 1122], ["In", 1124], ["this", 1127], ["final", 1132], ["analysis", 1138], [",", 1146], ["we", 1148], ["present", 1151], ["data", 1159], ["for", 1164], ["the", 1168], ["efficacy", 1172], ["of", 1181], ["the", 1184], ["booster", 1188], ["on", 1196], ["the", 1199], ["occurrence", 1203], ["of", 1214], ["malaria", 1217], [".", 1224], ["Vaccine", 1226], ["efficacy", 1234], ["(", 1243], ["VE", 1244], [")", 1246], ["against", 1248], ["clinical", 1256], ["malaria", 1265], ["was", 1273], ["analysed", 1277], ["by", 1286], ["negative", 1289], ["binomial", 1298], ["regression", 1307], ["and", 1318], ["against", 1322], ["severe", 1330], ["malaria", 1337], ["by", 1345], ["relative", 1348], ["risk", 1357], ["reduction", 1362], [".", 1371], ["This", 1373], ["trial", 1378], ["is", 1384], ["registered", 1387], ["with", 1398], ["ClinicalTrials.gov", 1403], [",", 1421], ["number", 1423], ["NCT00866619", 1430], [".", 1441], ["8922", 1443], ["children", 1448], ["and", 1457], ["6537", 1461], ["young", 1466], ["infants", 1472], ["were", 1480], ["included", 1485], ["in", 1494], ["the", 1497], ["modified", 1501], ["intention", 1510], ["-", 1519], ["to", 1520], ["-", 1522], ["treat", 1523], ["analyses", 1529], [".", 1537], ["Children", 1539], ["were", 1548], ["followed", 1553], ["up", 1562], ["for", 1565], ["a", 1569], ["median", 1571], ["of", 1578], ["48", 1581], ["months", 1584], ["(", 1591], ["IQR", 1592], ["39", 1596], ["-", 1598], ["50", 1599], [")", 1601], ["and", 1603], ["young", 1607], ["infants", 1613], ["for", 1621], ["38", 1625], ["months", 1628], ["(", 1635], ["34", 1636], ["-", 1638], ["41", 1639], [")", 1641], ["after", 1643], ["dose", 1649], ["1", 1654], [".", 1655], ["From", 1657], ["month", 1662], ["0", 1668], ["until", 1670], ["study", 1676], ["end", 1682], [",", 1685], ["compared", 1687], ["with", 1696], ["9585", 1701], ["episodes", 1706], ["of", 1715], ["clinical", 1718], ["malaria", 1727], ["that", 1735], ["met", 1740], ["the", 1744], ["primary", 1748], ["case", 1756], ["definition", 1761], ["in", 1772], ["children", 1775], ["in", 1784], ["the", 1787], ["C3C", 1791], ["group", 1795], [",", 1800], ["6616", 1802], ["episodes", 1807], ["occurred", 1816], ["in", 1825], ["the", 1828], ["R3R", 1832], ["group", 1836], ["(", 1842], ["VE", 1843], ["36\u00b73", 1846], ["%", 1850], [",", 1851], ["95", 1853], ["%", 1855], ["CI", 1857], ["31\u00b78", 1860], ["-", 1864], ["40\u00b75", 1865], [")", 1869], ["and", 1871], ["7396", 1875], ["occurred", 1880], ["in", 1889], ["the", 1892], ["R3C", 1896], ["group", 1900], ["(", 1906], ["28\u00b73", 1907], ["%", 1911], [",", 1912], ["23\u00b73", 1914], ["-", 1918], ["32\u00b79", 1919], [")", 1923], [";", 1924], ["compared", 1926], ["with", 1935], ["171", 1940], ["children", 1944], ["who", 1953], ["experienced", 1957], ["at", 1969], ["least", 1972], ["one", 1978], ["episode", 1982], ["of", 1990], ["severe", 1993], ["malaria", 2000], ["in", 2008], ["the", 2011], ["C3C", 2015], ["group", 2019], [",", 2024], ["116", 2026], ["children", 2030], ["experienced", 2039], ["at", 2051], ["least", 2054], ["one", 2060], ["episode", 2064], ["of", 2072], ["severe", 2075], ["malaria", 2082], ["in", 2090], ["the", 2093], ["R3R", 2097], ["group", 2101], ["(", 2107], ["32\u00b72", 2108], ["%", 2112], [",", 2113], ["13\u00b77", 2115], ["to", 2120], ["46\u00b79", 2123], [")", 2127], ["and", 2129], ["169", 2133], ["in", 2137], ["the", 2140], ["R3C", 2144], ["group", 2148], ["(", 2154], ["1\u00b71", 2155], ["%", 2158], [",", 2159], ["-23\u00b70", 2161], ["to", 2167], ["20\u00b75", 2170], [")", 2174], [".", 2175], ["In", 2177], ["young", 2180], ["infants", 2186], [",", 2193], ["compared", 2195], ["with", 2204], ["6170", 2209], ["episodes", 2214], ["of", 2223], ["clinical", 2226], ["malaria", 2235], ["that", 2243], ["met", 2248], ["the", 2252], ["primary", 2256], ["case", 2264], ["definition", 2269], ["in", 2280], ["the", 2283], ["C3C", 2287], ["group", 2291], [",", 2296], ["4993", 2298], ["episodes", 2303], ["occurred", 2312], ["in", 2321], ["the", 2324], ["R3R", 2328], ["group", 2332], ["(", 2338], ["VE", 2339], ["25\u00b79", 2342], ["%", 2346], [",", 2347], ["95", 2349], ["%", 2351], ["CI", 2353], ["19\u00b79", 2356], ["-", 2360], ["31\u00b75", 2361], [")", 2365], ["and", 2367], ["5444", 2371], ["occurred", 2376], ["in", 2385], ["the", 2388], ["R3C", 2392], ["group", 2396], ["(", 2402], ["18\u00b73", 2403], ["%", 2407], [",", 2408], ["11\u00b77", 2410], ["-", 2414], ["24\u00b74", 2415], [")", 2419], [";", 2420], ["and", 2422], ["compared", 2426], ["with", 2435], ["116", 2440], ["infants", 2444], ["who", 2452], ["experienced", 2456], ["at", 2468], ["least", 2471], ["one", 2477], ["episode", 2481], ["of", 2489], ["severe", 2492], ["malaria", 2499], ["in", 2507], ["the", 2510], ["C3C", 2514], ["group", 2518], [",", 2523], ["96", 2525], ["infants", 2528], ["experienced", 2536], ["at", 2548], ["least", 2551], ["one", 2557], ["episode", 2561], ["of", 2569], ["severe", 2572], ["malaria", 2579], ["in", 2587], ["the", 2590], ["R3R", 2594], ["group", 2598], ["(", 2604], ["17\u00b73", 2605], ["%", 2609], [",", 2610], ["95", 2612], ["%", 2614], ["CI", 2616], ["-9\u00b74", 2619], ["to", 2624], ["37\u00b75", 2627], [")", 2631], ["and", 2633], ["104", 2637], ["in", 2641], ["the", 2644], ["R3C", 2648], ["group", 2652], ["(", 2658], ["10\u00b73", 2659], ["%", 2663], [",", 2664], ["-17\u00b79", 2666], ["to", 2672], ["31\u00b78", 2675], [")", 2679], [".", 2680], ["In", 2682], ["children", 2685], [",", 2693], ["1774", 2695], ["cases", 2700], ["of", 2706], ["clinical", 2709], ["malaria", 2718], ["were", 2726], ["averted", 2731], ["per", 2739], ["1000", 2743], ["children", 2748], ["(", 2757], ["95", 2758], ["%", 2760], ["CI", 2762], ["1387", 2765], ["-", 2769], ["2186", 2770], [")", 2774], ["in", 2776], ["the", 2779], ["R3R", 2783], ["group", 2787], ["and", 2793], ["1363", 2797], ["per", 2802], ["1000", 2806], ["children", 2811], ["(", 2820], ["995", 2821], ["-", 2824], ["1797", 2825], [")", 2829], ["in", 2831], ["the", 2834], ["R3C", 2838], ["group", 2842], [".", 2847], ["The", 2849], ["numbers", 2853], ["of", 2861], ["cases", 2864], ["averted", 2870], ["per", 2878], ["1000", 2882], ["young", 2887], ["infants", 2893], ["were", 2901], ["983", 2906], ["(", 2910], ["95", 2911], ["%", 2913], ["CI", 2915], ["592", 2918], ["-", 2921], ["1337", 2922], [")", 2926], ["in", 2928], ["the", 2931], ["R3R", 2935], ["group", 2939], ["and", 2945], ["558", 2949], ["(", 2953], ["158", 2954], ["-", 2957], ["926", 2958], [")", 2961], ["in", 2963], ["the", 2966], ["R3C", 2970], ["group", 2974], [".", 2979], ["The", 2981], ["frequency", 2985], ["of", 2995], ["SAEs", 2998], ["overall", 3003], ["was", 3011], ["balanced", 3015], ["between", 3024], ["groups", 3032], [".", 3038], ["However", 3040], [",", 3047], ["meningitis", 3049], ["was", 3060], ["reported", 3064], ["as", 3073], ["a", 3076], ["SAE", 3078], ["in", 3082], ["22", 3085], ["children", 3088], [":", 3096], ["11", 3098], ["in", 3101], ["the", 3104], ["R3R", 3108], ["group", 3112], [",", 3117], ["ten", 3119], ["in", 3123], ["the", 3126], ["R3C", 3130], ["group", 3134], [",", 3139], ["and", 3141], ["one", 3145], ["in", 3149], ["the", 3152], ["C3C", 3156], ["group", 3160], [".", 3165], ["The", 3167], ["incidence", 3171], ["of", 3181], ["generalised", 3184], ["convulsive", 3196], ["seizures", 3207], ["within", 3216], ["7", 3223], ["days", 3225], ["of", 3230], ["RTS", 3233], [",", 3236], ["S", 3237], ["/", 3238], ["AS01", 3239], ["booster", 3244], ["was", 3252], ["2\u00b72", 3256], ["per", 3260], ["1000", 3264], ["doses", 3269], ["in", 3275], ["young", 3278], ["infants", 3284], ["and", 3292], ["2\u00b75", 3296], ["per", 3300], ["1000", 3304], ["doses", 3309], ["in", 3315], ["children", 3318], [".", 3326], ["RTS", 3328], [",", 3331], ["S", 3332], ["/", 3333], ["AS01", 3334], ["prevented", 3339], ["a", 3349], ["substantial", 3351], ["number", 3363], ["of", 3370], ["cases", 3373], ["of", 3379], ["clinical", 3382], ["malaria", 3391], ["over", 3399], ["a", 3404], ["3", 3406], ["-", 3407], ["4", 3408], ["year", 3410], ["period", 3415], ["in", 3422], ["young", 3425], ["infants", 3431], ["and", 3439], ["children", 3443], ["when", 3452], ["administered", 3457], ["with", 3470], ["or", 3475], ["without", 3478], ["a", 3486], ["booster", 3488], ["dose", 3496], [".", 3500], ["Efficacy", 3502], ["was", 3511], ["enhanced", 3515], ["by", 3524], ["the", 3527], ["administration", 3531], ["of", 3546], ["a", 3549], ["booster", 3551], ["dose", 3559], ["in", 3564], ["both", 3567], ["age", 3572], ["categories", 3576], [".", 3586], ["Thus", 3588], [",", 3592], ["the", 3594], ["vaccine", 3598], ["has", 3606], ["the", 3610], ["potential", 3614], ["to", 3624], ["make", 3627], ["a", 3632], ["substantial", 3634], ["contribution", 3646], ["to", 3659], ["malaria", 3662], ["control", 3670], ["when", 3678], ["used", 3683], ["in", 3688], ["combination", 3691], ["with", 3703], ["other", 3708], ["effective", 3714], ["control", 3724], ["measures", 3732]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0c2e363266584674a6c79cd1c7d3e1eb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[34, 36]], "char_spans": [[203, 209]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["chromosome", 84], [",", 94], ["which", 96], ["is", 102], ["associated", 105], ["with", 116], ["a", 121], ["balanced", 123], ["translocation", 132], ["involving", 146], ["chromosomes", 156], ["9", 168], ["and", 170], ["22", 174], ["to", 177], ["produce", 180], ["a", 188], ["fusion", 190], ["gene", 197], ["(", 202], ["bcr", 203], ["-", 206], ["abl", 207], [")", 210], ["that", 212], ["gives", 217], ["rise", 223], ["to", 228], ["a", 231], ["constitutively", 233], ["activated", 248], ["Abl", 258], ["tyrosine", 262], ["kinase", 271], [".", 277], ["This", 279], ["kinase", 284], ["led", 291], ["to", 295], ["the", 298], ["discovery", 302], ["of", 312], ["several", 315], ["small", 323], ["-", 328], ["molecule", 329], ["inhibitors", 338], [",", 348], ["imatinib", 350], ["being", 359], ["the", 365], ["first", 369], ["and", 375], ["most", 379], ["successful", 384], ["of", 395], ["these", 398], [".", 403], ["Resistance", 405], ["to", 416], ["imatinib", 419], ["results", 428], ["in", 436], ["some", 439], ["patients", 444], ["from", 453], ["Abl", 458], ["kinase", 462], ["point", 469], ["mutations", 475], [".", 484], ["Overcoming", 486], ["imatinib", 497], ["resistance", 506], ["represents", 517], ["one", 528], ["of", 532], ["the", 535], ["biggest", 539], ["challenges", 547], ["facing", 558], ["clinicians", 565], ["in", 576], ["the", 579], ["modern", 583], ["management", 590], ["of", 601], ["CML", 604], [".", 607], ["In", 609], ["this", 612], ["review", 617], [",", 623], ["we", 625], ["discuss", 628], ["the", 636], ["current", 640], ["understanding", 648], ["of", 662], ["CML", 665], ["pathophysiology", 669], ["and", 685], ["mechanisms", 689], ["of", 700], ["imatinib", 703], ["resistance", 712], ["and", 723], ["how", 727], ["advancing", 731], ["this", 741], ["knowledge", 746], ["has", 756], ["led", 760], ["to", 764], ["the", 767], ["design", 771], ["of", 778], ["novel", 781], ["therapies", 787], ["in", 797], ["the", 800], ["area", 804], ["of", 809], ["blastic", 812], ["phase", 820], ["CML", 826], ["and", 830], ["Philadelphia", 834], ["chromosome", 847], ["-", 857], ["positive", 858], ["acute", 867], ["lymphoblastic", 873], ["leukemia", 887], ["with", 896], ["previous", 901], ["imatinib", 910], ["failure", 919], [".", 926]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
